JAMA Editors' Summary: On research in medicine, science,& clinical practice. For physicians, researchers,& clinicians. / Type 2 Diabetes Treatments and Major Adverse Cardiovascular Events by Age and Sex, Simvastatin with Rifaximin for Decompensated Liver Cirrhosis, Approved vs Off-label Doxepin Formulation Trends and more

Subtitle: Editor’s Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from .
Duration: 09:51
Publishing date: 2025-02-07 16:05
Link: https://edhub.ama-assn.org/jn-learning/audio-player/10.1001/jama.2025.636
Contributors
Enclosures: https://traffic.libsyn.com/secure/jamaeditorsaudiosummary/Type_2_Diabetes_Treatments_and_Major_Adverse_Cardiovascular_Events_by_Age_and_Sex_Simvastatin_with_Rifaximin_for_Decompensated_Liver_Cirrhosis_Approved_vs_Off-label_Doxepin_Formulation_Trends_and; audio/mpeg

Shownotes

Editor’s Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from February 1-7, 2025.